$2.79 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 103 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
New | DEXCOM INCnote 0.750% 5/1 | $84,160,000 | – | 55,000,000 | +100.0% | 3.02% | – | |
NVRO | New | NEVRO CORP | $29,927,000 | – | 525,040 | +100.0% | 1.07% | – |
VCEL | New | VERICEL CORP | $22,891,000 | – | 1,617,730 | +100.0% | 0.82% | – |
ARVN | New | ARVINAS INC | $20,813,000 | – | 1,233,734 | +100.0% | 0.75% | – |
FATE | New | FATE THERAPEUTICS INC | $19,118,000 | – | 1,173,617 | +100.0% | 0.68% | – |
DPLO | New | DIPLOMAT PHARMACY INC | $16,570,000 | – | 853,687 | +100.0% | 0.59% | – |
KALV | New | KALVISTA PHARMACEUTICALS INC | $14,372,000 | – | 650,000 | +100.0% | 0.52% | – |
NITE | New | NIGHTSTAR THERAPEUTICS PLCadr | $10,210,000 | – | 499,747 | +100.0% | 0.37% | – |
ALLK | New | ALLAKOS INC | $10,123,000 | – | 225,000 | +100.0% | 0.36% | – |
LIVN | New | LIVANOVA PLC | $8,864,000 | – | 71,500 | +100.0% | 0.32% | – |
QURE | New | UNIQURE NV | $8,786,000 | – | 241,430 | +100.0% | 0.32% | – |
KPTI | New | KARYOPHARM THERAPEUTICS INC | $8,089,000 | – | 475,000 | +100.0% | 0.29% | – |
VKTX | New | VIKING THERAPEUTICS INC | $8,013,000 | – | 460,000 | +100.0% | 0.29% | – |
INSP | New | INSPIRE MED SYS INC | $7,953,000 | – | 189,000 | +100.0% | 0.28% | – |
ADUS | New | ADDUS HOMECARE CORP | $4,601,000 | – | 65,590 | +100.0% | 0.16% | – |
CNST | New | CONSTELLATION PHARMCETICLS I | $4,279,000 | – | 635,843 | +100.0% | 0.15% | – |
SVRA | New | SAVARA INC | $2,790,000 | – | 250,000 | +100.0% | 0.10% | – |
RMED | New | RA MED SYS INC | $2,341,000 | – | 128,600 | +100.0% | 0.08% | – |
PTXTQ | New | PERNIX THERAPEUTICS HLDGS IN | $635,000 | – | 658,826 | +100.0% | 0.02% | – |
HSGX | New | HISTOGENICS CORP | $161,000 | – | 296,099 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
CENTENE CORP DEL | 33 | Q2 2024 | 3.3% |
BIOCRYST PHARMACEUTICALS INC | 32 | Q2 2024 | 2.2% |
MOLINA HEALTHCARE INC | 27 | Q2 2024 | 1.7% |
BROOKDALE SR LIVING INC | 26 | Q2 2024 | 2.2% |
EHEALTH INC | 25 | Q3 2020 | 2.0% |
INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
DECIPHERA PHARMACEUTICALS IN | 24 | Q1 2024 | 2.0% |
MYLAN NV | 23 | Q3 2020 | 6.2% |
PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
4 | 2024-09-17 |
3 | 2024-09-12 |
N-PX | 2024-08-29 |
13F-HR | 2024-08-14 |
4 | 2024-07-17 |
4 | 2024-07-15 |
4 | 2024-07-11 |
4 | 2024-06-14 |
4 | 2024-06-03 |
13F-HR | 2024-05-15 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.